[Direct answer]In the Beijing area, if a participant suffers harm during a new drug clinical trial, the party liable for compensation is determined based on the trial organization and the party at fault, typically including the sponsor (pharmaceutical company) and the trial institution (hospital). According to Article 108 of the Civil Code of the People's Republic of China (effective January 1, 2021), clinical trials must be approved by the competent authorities and subject to ethical review, and the written consent of the subjects must be obtained. If the subjects suffer harm, the relevant parties shall bear tort liability in accordance with the law. The "Quality Management Standards for Drug Clinical Trials" (effective July 1, 2020) also require sponsors to establish compensation or insurance mechanisms. To protect their rights, they should collect informed consent forms, trial protocols, medical records of harm, and causal evidence to clarify the responsible parties. It is recommended to retain all trial documents and consult professional lawyers in a timely manner. For more details, please refer to the following link:Legal services for personal injury and medical disputes.

I. Problem Background and Typical Scenarios

In clinical trials of new drugs, injuries often occur in tumors, rare diseases, and early-stage trials of innovative drugs. Typical scenarios include: unexpected severe adverse reactions to the experimental drug, organ damage to the subjects; harm caused by improper protocol design or dosing; institutions failing to fully inform the risks, with subjects signing consent forms without understanding the situation; suspension of the trial without proper follow-up arrangements; and sponsors evading compensation by citing "inherent risks of the trial". Subjects are often in an information-disadvantaged position, knowing little about the protocol, risks, and compensation agreements. Such disputes involve both medical and contractual aspects, and clarifying the defects in informed consent and the causality of the harm is crucial. For other medical research, relevant provisions can be referenced.Special services and other case servicesAnalysis and judgment.

II. Key points of contention

There are three key points of contention. Firstly, the flaw in informed consent: whether the risks were fully disclosed, whether there was ethical review and written consent, which directly affect the responsibilities of institutions and sponsors. Secondly, the causality between harm and the trial: whether the harm was caused by the experimental drugs or protocols, and how to distinguish it from the subjects' own diseases, which requires professional appraisal. Thirdly, the allocation of responsibilities: sponsors and trial institutions share their respective obligations according to GCP, and whether the insurance and compensation mechanisms are activated also affect the compensation. In practice, sponsors often defend themselves with arguments such as "known risks" and "progression of their own diseases", which require resolving through the protocol and medical records.

III. Professional analysis by Hengluo Lawyers

Based on practical observations in handling clinical trial disputes, subjects are most likely to be passive in the event of "documentation deficiencies". Many participants fail to keep informed consent forms, trial protocols, and follow-up records, making it difficult to prove the existence of informed consent and the extent of the damage after an injury; some institutions also shift all the risks to the "inherent dangers of the trial". Hengluo Lawyers usually recommend the following: request and keep informed consent forms and protocols before participating in the trial, fix medical records, tests, and images after an injury, apply for causality identification, verify the sponsor's insurance or compensation agreements, and clarify the chain of responsibility. For cases involving trial contracts and insurance relationships, legal assistance can be sought.Business and contract dispute services for enterprisesClarify the obligation to provide compensation.

IV. Practical suggestions and legal basis

The legal basis includes Article 108 of the Civil Code of the People's Republic of China (effective January 1, 2021) on informed consent and subject protection in clinical trials; the provisions on drug clinical trial approval and subject rights protection in the Pharmaceutical Administration Law of the People's Republic of China (effective December 1, 2019); the regulations on sponsor compensation, insurance, and institutional obligations in the Good Clinical Practice Guidelines for Drug Clinical Trials (effective July 1, 2020); and the Regulations on the Prevention and Handling of Medical Disputes (effective October 1, 2018). Practical suggestions include: preserving informed consent and trial protocols, documenting medical records after injury, applying for causality assessments, verifying compensation insurance, and filing claims after identifying responsible parties. For cases involving overlapping claims for medical harm, relevant parties may refer to the above-mentioned legal provisions for resolution.Personal injury and medical dispute servicesCoordinate and plan things in an organized and efficient way to achieve a specific goal or complete a task.

5. Hengluo Law Firm's Advice

For injuries occurring during clinical trials of new drugs, first confirm whether there is "legal consent and ethical approval". If there is insufficient disclosure, no written consent, or operations exceeding the trial protocol, the responsibility will be greater; even if informed, additional damages beyond the inherent risks of the trial can still be claimed for compensation. Never accept the evasive response of "once you sign, there's no compensation", nor settle the matter hastily when the documents are incomplete. Keep the informed consent form, the trial protocol, and all medical records, and verify whether the sponsor has purchased insurance or established a compensation fund. It is recommended to consult a professional lawyer as soon as possible, apply for an appraisal in accordance with the law, and establish the causality and basis for compensation.

VI. Frequently Asked Questions

Q1: If I get injured while participating in a new drug clinical trial, am I guaranteed to receive compensation?

It does not depend on the outcome commitment, but on the disclosure of defects, faults, and causality. If the trial causes harm due to insufficient disclosure, lack of ethical approval, or improper execution of the plan, according to Article 108 of the Civil Code and GCP, the sponsors and institutions should bear responsibility and initiate compensation; if the damage is a known risk that has been fully disclosed and is unrelated to the operation, it is more difficult to obtain compensation. The success or failure of the practice depends on the evidence: whether the informed consent is standard, and whether there is a causal relationship between the damage and the trial. It is recommended to keep the documents and apply for appraisal, and then claim rights, which can be combined with other evidence.Special services and other case servicesEvaluation.

Q2: If I am injured during a clinical trial, what evidence do I need to prepare?

The core evidence includes: informed consent forms and trial protocols (to prove that the informed consent content has been disclosed and approved), subject identification numbers and enrollment records, records of the distribution and administration of trial drugs, outpatient and hospitalization medical records after injury, examination images and diagnoses, follow-up and discontinuation of medication records, sponsor qualifications and insurance or compensation agreements, as well as communication records. The evidence is organized around the "legal consent - trial conduct - harm occurrence - causality" framework. It is essential to keep the documents on file and not just submit them to the institution. Only with complete materials can claims for liability and compensation be supported.

Q3: How much does it cost to seek legal redress for injuries sustained during clinical trials?

The litigation fees shall be calculated in accordance with the "Measures for the Payment of Litigation Fees" and accumulated in stages based on the amount of the litigation request, to be borne by the losing party. The claimed medical expenses, disability compensation, etc. constitute the subject matter. Lawyer's fees are charged based on the appraisal and workload, subject to the contract of entrustment, with no unified standard. Under GCP, applicants are generally required to set up compensation or insurance, and the relevant appraisal fees can be claimed to be borne by them. It is recommended to first calculate the damage and compensation expectations and weigh the costs; in many cases, it is possible to first use the applicant's compensation mechanism, and if it fails, then litigation can be initiated to control expenses.

Q4: For injuries sustained during clinical trials, how long does it typically take to receive compensation?

The duration of the process varies depending on the path taken. For those who first use the compensation mechanism provided by the applicant, the process may take several weeks to months, depending on their internal procedures. For those requiring appraisal, the causality appraisal typically takes several weeks to months. For litigation, the ordinary procedure for the first instance takes six months, and the summary procedure takes three months. For complex cases or appeals, the duration will be even longer. Overall, it may take more than half a year or even a year from the time of claiming to receiving the compensation. It is recommended to fix the evidence and initiate compensation negotiations simultaneously after the injury, so as to avoid delaying the process by waiting for litigation. For those with clear responsibilities, priority should be given to mediation to shorten the process.

Q5: If I get injured while participating in a clinical trial for a new drug, what should I do first?

Here's the translation of the Chinese (Simplified) sentence into English, with a detailed explanation: Suggested four steps: First, immediately stop the experimental medication and seek medical attention, documenting the injury history, tests, and imaging results. Second, retrieve and preserve the informed consent forms, trial protocols, and enrollment records, verifying the ethical approval and disclosure content. Third, verify the sponsor's compensation or insurance agreements, submit a written claim for compensation, and retain all relevant evidence. Fourth, if no agreement is reached, apply for a causality assessment and initiate legal action, clarifying the responsibilities of the sponsor and the institution. Maintain all relevant documents throughout the process and, if necessary, engage a lawyer. For reference, please refer to the following sources:Personal injury and medical dispute servicesObtain assistance.

The above Q&A is mainly based on the judicial practice in the Beijing area. There may be differences in the adjudication standards in different regions. It is recommended to consult a professional lawyer based on the specific circumstances of the case.

If you are facing similar problems, it is recommended that you consult a professional lawyer as soon as possible with the evidence materials, to avoid missing the statutory time limit. →Personal injury legal services·Beijing Henglu Law Firm

Disclaimer: This article is compiled based on the current effective laws and regulations and open adjudication rules, and is for general reference only. It does not constitute a formal legal opinion on specific cases. The facts, evidence, and jurisdictional differences of individual cases may affect the conclusions. In the event of a dispute, please consult a practicing lawyer in a timely manner.